What are the current analyst ratings and price targets for CLSD?

The current analyst ratings and price targets for Clearside Biomedical Inc. (CLSD) are as follows:

1. **Needham**: Rated CLSD as "Hold" with a price target of $3.00. This rating was downgraded from "Buy," citing difficulties in securing funding for its CLS-AX program.
2. **HC Wainwright & Co.**: Rated CLSD as "Neutral" with a price target of $5.00. This rating maintained a "Strong Buy" consensus despite the downgrade.
3. **Chardan Capital**: Also rated CLSD as "Neutral" with a price target of $3.50, which maintained a "Strong Buy" consensus.

In summary, the current analyst ratings for CLSD are mixed, with one "Hold" rating and two "Neutral" ratings. The price targets range from $3.00 to $5.00, indicating a potential upside from the current trading price of $0.48. However, it's important to note that the recent downgrades reflect the challenges the company faces in securing funding and the uncertainty surrounding its future development path.